ALK and non-small cell lung carcinoma: In NSCLC, EGFRexon19del (n = 5), EGFRL858R (n = 2), EGFRT790M (n = 7), and ALK fusion (n = 1) were targeted, with 13 patients achieving PR and two SD for a RR of 87% (95% CI, 58% to 98%) and a DCR of 100% (95% CI, 75% to 100%; Table 4, Fig 2C).